What could health technology assessment learn from living clinical practice guidelines?
A “living” approach to clinical practice guidelines is when the identification, appraisal and synthesis of evidence is maintained and repeated at an agreed frequency, with a clear process for when and how new evidence is to be incorporated. The value of a living approach to guidelines was emphasised...
Main Authors: | Saskia Cheyne, Samantha Chakraborty, Samara Lewis, Sue Campbell, Tari Turner, Sarah Norris |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1234414/full |
Similar Items
-
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01) -
Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
by: Joost J. Enzing, et al.
Published: (2022-08-01) -
Reimbursement decision-making system in Poland systematically compared to other countries
by: Aneta Mela, et al.
Published: (2023-10-01) -
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01) -
Snake Oil or Super Drug: How Have Regulators and Payers Perceived New Medicines that Target Asymptomatic Conditions?
by: Brian Richard Needham
Published: (2023-11-01)